OncoMatch/Clinical Trials/NCT07379476
Local Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer
Is NCT07379476 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Osimertinib alone for lung cancer (nsclc).
Treatment: Osimertinib alone — This is an open-label, multicentre, randomized phase II clinical trial. Patients with stage IV (AJCC 9th edition) non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletion or exon 21 L858R mutation, who had less than or equal to 3 active oligoresidual cancer sites amenable to local ablative therapy (LAT) (as determined by physician) after 3-6 months of firstline osimertinib treatment, are eligible. Subjects will be randomized 1:1 to osimertinib with or without LAT.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR exon 19 deletion
Required: EGFR l858r
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: EGFR tyrosine kinase inhibitor (osimertinib) — first line for stage IV disease
Receive first line osimertinib monotherapy for stage IV disease
Lab requirements
Blood counts
haemoglobin ≥9.0g/dL, absolute neutreophil count ≥1.0 x 10^9/L, platelet count ≥100 x 10^9/L
Kidney function
creatinine clearance ≥30ml/min, according to the formula of Cockcroft-Gault equation
Liver function
bilirubin ≤1.5 x ULN, AST/ALT ≤2.5 x ULN
Adequate haematological values: haemoglobin ≥9.0g/dL, absolute neutreophil count ≥1.0 x 10^9/L, platelet count ≥100 x 10^9/L; Adequate hepatic function: bilirubin ≤1.5 x ULN, AST/ALT ≤2.5 x ULN; Adequate renal function: creatinine clearance ≥30ml/min, according to the formula of Cockcroft-Gault equation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07379476 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received EGFR tyrosine kinase inhibitor.
Does this trial require EGFR?
Yes, EGFR exon 19 deletion is a required biomarker for enrollment.
Does this trial require EGFR?
Yes, EGFR l858r is a required biomarker for enrollment.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages